Board of Directors | Microbes BioSciences

Brian W. Pusch

Brian W. Pusch has served as Chairman of the Board and sole Chief Executive Officer and President since 2018. From 2012 to 2018 he served as Co-Chief Executive Officer of Microbes. He joined the Board of Directors in 1997.

Brian has been involved in founding, financing and advising technology startup companies for nearly 35 years. In 2016 he co-founded Inozyme Pharma, Inc., which is developing enzyme replacement therapies for diseases of aberrant calcification based on the ENPP family of enzymes. Inozyme closed its Series A venture capital round of $49.5 million in January 2017, subsequently raised an additional $67 million in a Series A2 round and completed its IPO in July 2020.

Over the years Brian has been a member of teams that have founded, built and financed a number of successful technology startups, including 5 successful exits ranging from $500 million to $6.8 billion. In 1992 he founded Pusch & Gal, a New York City boutique law firm, after a successful career, first as an associate and then as a partner, of a leading Wall Street law firm.

He also serves on the boards of Evrys Bio, LLC (host-targeted antiviral therapeutics based on sirtuins), InvivoSciences Inc. (3-dimensional tissue derived from induced pluripotent stem cells and used for drug discovery, screening and testing), Xiconic Pharmaceuticals, LLC (ADC oncology therapeutics), and Oncovir, Inc. (oncology and anti-viral therapeutics).

(A.B. in Interdisciplinary Studies of Economics and Government, The College of William & Mary in Virginia, 1976 (Phi Beta Kappa); J.D., University of Virginia, 1979.)

Lillian W. Chiang, Ph.D., MBA

Lillian Chiang served on the Microbes Board of. Directors from October 2010 to February 2017 and then returned to our Board in December 2018. She serves as President and Chief Executive Office of Evrys Bio, LLC, a company she co-founded in 2013 that is developing host-targeted antiviral therapeutics by targeting sirtuin proteins. Prior to Evrys Bio, Lillian was Vice President of Translational Medicine at Kadmon Corporation. She was responsible for strategy and translation from early discovery through proof of concept in man. Throughout her career she has built from scratch, state-of-the-art technologies, drug discovery & development teams, and businesses at Stanford, Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon.

At Aestus, she applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. Aestus’ successfully advanced it first in-licensed product from novel mechanism of action and therapeutic hypothesis to completion of a Phase 2A human clinical trial in 5 years at a cost of $5 million, funded primarily by government grants. BS, Massachusetts institute of Technology; Ph.D., University of Wisconsin; Post-Doc, Stanford University; MBA, The Wharton School of the University of Pennsylvania.

L. Marc Shegoski

Marc has 38 years of experience building long-lasting relationships with non-profits, foundations, endowments, retirement plans, and high net worth clients. As a UBS Senior Institutional Consultant, a designation held by only 28 of UBS‘s top Institutional Consultants, Marc specializes in asset allocation, manager due diligence, portfolio construction, and trading dynamics.

Marc was a partner in the development of the UBS Institutional Consulting Group, previously named PRIME Asset Consulting at Paine Webber & Kidder Peabody. With deep experience beyond consulting, Marc was a founding partner of a New York Stock Exchange firm, a Director of the Office State Courts Administrator for the State of Missouri and a Consultant to the Special Investigation Commission of the New Jersey Senate.

Marc is a board member of multiple charitable organizations in the greater Princeton-New Brunswick area and an adjunct instructor at Rutgers University and Rider University.

Thomas Lubinski

Tom Lubinski has served on the Microbes Board of Directors since June 2018.

He currently serves as an Advisory Board Member at Quantum Circuits Inc., a leading supplier of quantum computing systems, where he previously held the position of Chief Software Architect. Since 2016, he has overseen and provided strategic guidance on key developments in software architecture for the company’s advanced Quantum Computer Control System, ensuring architectural consistency across all layers of the complex quantum computing software stack. As Quantum Circuits’ representative to the Quantum Economic Development Consortium (QED-C), Tom chaired the Technical Advisory Committee on Standards and Performance Metrics for 3 years, and now leads coordination efforts among committee members to develop and champion application-oriented benchmarks for quantum computing.

Previously, Tom founded SL Corporation, which grew into a market leader in Real-Time Process Monitoring and Control Systems software for aerospace, factory automation, energy, transportation, and telecommunications industries. During his 37-year tenure as CEO and CTO, Tom guided the company through multiple generations of successful product development and commercialization, personally contributing to thousands of successful customer implementations of real-time computer application systems worldwide.